<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819649</url>
  </required_header>
  <id_info>
    <org_study_id>OUH-DK-PILOT-PRECISE</org_study_id>
    <nct_id>NCT01819649</nct_id>
  </id_info>
  <brief_title>Selenium in the Prevention of Cancer</brief_title>
  <acronym>DK PRECISE</acronym>
  <official_title>Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The K.A. Rohde and Wife Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The County of Funen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cypress Systems, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Dagmar Marshall Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The N. O. Andersen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Directory of Food and Agriculture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Foundation of Clinical Experimental Cancer Research, Odense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Foundation of Lily Benthine Lund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Memory Foundation of Merchant Brogaard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharma Nord</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study proceeding an intended international trial.

      Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast
      tablets will reduce the risk of cancer in healthy individuals.

      Objective: The objective of this pilot study was to assess the viability of a full scale
      randomised trial.

      AMENDMENT TO STUDY OBJECTIVE: Mortality analysis during intervention and follow-up as
      specified in the sections concerning study design and outcome measures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>AMENDMENT TO STUDY DESIGN: Towards the end of the intervention period, it was decided to follow-up participants for an additional ten years via Danish public registries for data on morbidity and mortality.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viability of full scale study</measure>
    <time_frame>At five years intervention</time_frame>
    <description>At five years intervention (last participant last visit was june 2004) viability of full scale study was assessed according to the drop out rate, cost etc. of this pilot study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMENDMENT TO OUTCOME MEASURES: Mortality analysis.</measure>
    <time_frame>Up to 17 years</time_frame>
    <description>Study participants will be followed up for mortality from the date of randomization in 1998-1999 through March 31, 2015. Vital status and date of death will be obtained from the Danish Civil Registration System. Information on the underlying cause of death will be obtained from the Danish Registry of Causes of Death through December 31, 2010 and from participant medical charts from January 1, 2011. Cause of death will be classified according to the 10th Revision of the International Classification of Diseases as death due to cancer (codes C00-C97), CVD (I00-I99), and all other causes.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">491</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Yeast tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S</intervention_name>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d</arm_group_label>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d</arm_group_label>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d</arm_group_label>
    <arm_group_label>Yeast tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO performance status 0 or 1

          -  No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic
             phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range)

          -  No previous cancer diagnosis

          -  No known HIV-infection

          -  Participant must understand oral and written information

          -  Participant must not use selenium supplementation of above 50 mcg/d

          -  Participant must give written consent prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Selenium Centre, Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>SÃ¸ren Cold</investigator_full_name>
    <investigator_title>M.D. PhD</investigator_title>
  </responsible_party>
  <keyword>selenium</keyword>
  <keyword>selenium supplementation</keyword>
  <keyword>randomised controlled trial</keyword>
  <keyword>prevention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

